Find Levomethadyl Acetate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Levacetylmethadol, Laam, Levo-alphacetylmethadol, Levomethadyl, Orlaam, 1-alpha-acetylmethadol
Molecular Formula
C23H31NO2
Molecular Weight
353.5  g/mol
InChI Key
XBMIVRRWGCYBTQ-AVRDEDQJSA-N
FDA UNII
R3B637Y991

Levomethadyl Acetate
A narcotic analgesic with a long onset and duration of action.
1 2D Structure

Levomethadyl Acetate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate
2.1.2 InChI
InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3/t18-,22-/m0/s1
2.1.3 InChI Key
XBMIVRRWGCYBTQ-AVRDEDQJSA-N
2.1.4 Canonical SMILES
CCC(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C
2.1.5 Isomeric SMILES
CC[C@@H](C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C
2.2 Other Identifiers
2.2.1 UNII
R3B637Y991
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (3r,6r)-3-acetoxy-6-dimethylamino-4,4-diphenylheptane

2. 6-(dimethylamino)-4,4-diphenyl-3-heptanol Acetate

3. Acemethadone

4. Acetylmethadol

5. Alphacetylmethadol

6. Amidolacetate

7. Dimepheptanol

8. Laam

9. Levo Alpha Acetylmethadol

10. Levo-alpha-acetylmethadol

11. Levoacetylmethadol

12. Levomethadyl

13. Levomethadyl Acetate Hydrochloride

14. Methadol

15. Methadyl Acetate

16. Orlaam

2.3.2 Depositor-Supplied Synonyms

1. Levacetylmethadol

2. Laam

3. Levo-alphacetylmethadol

4. Levomethadyl

5. Orlaam

6. 1-alpha-acetylmethadol

7. Levo-methadyl Acetate

8. 1477-40-3

9. (-)-alpha-acetylmethadol

10. Levo-alpha-acetylmethadol

11. Levacetilmetadol

12. Alpha-l-acetylmethadol

13. Levacetylmethadolum

14. Levacetylmethadol [inn]

15. Alpha-(-)-acetylmethadol

16. Levacetilmetadol [inn-spanish]

17. Levacetylmethadolum [inn-latin]

18. L-alpha-acetylmethadol

19. Levoacetyl Methadol

20. Levomethadyl Acetate [usan]

21. Dea No. 9648

22. (-)-6-(dimethylamino)-4,4-diphenyl-3-heptanol Acetate (ester)

23. Laa-m

24. Levacetylmethadol (inn)

25. 34433-66-4

26. Levomethadyl Acetate (usan)

27. Chebi:6441

28. (1s,4s)-4-(dimethylamino)-1-ethyl-2,2-diphenylpentyl Acetate

29. [(3s,6s)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] Acetate

30. R3b637y991

31. N-alpha-acetylmethadol

32. (3s,6s)-6-(dimethylamino)-4,4-diphenylheptan-3-yl Acetate

33. Benzeneethanol, Beta-((2s)-2-(dimethylamino)propyl)-alpha-ethyl-beta-phenyl-, Acetate (ester), (alphas)-

34. Benzeneethanol, Beta-(2-(dimethylamino)propyl)-alpha-ethyl-beta-phenyl-, Acetate (ester), (s-(r*,r*))-

35. Unii-r3b637y991

36. 3-heptanol, 6-(dimethylamino)-4,4-diphenyl-, Acetate (ester), (3s,6s)-(-)-

37. Benzeneethanol, Beta-[(2s)-2-(dimethylamino)propyl]-alpha-ethyl-beta-phenyl-, Acetate (ester), (alphas)-

38. Benzeneethanol, Beta-[2-(dimethylamino)propyl]-alpha-ethyl-beta-phenyl-, Acetate (ester), [s-(r*,r*)]-

39. Chembl1514

40. Bidd:pxr0155

41. Schembl93805

42. Bidd:gt0373

43. Gtpl7212

44. Dtxsid3023211

45. Levacetylmethadol [mart.]

46. Levomethadyl Acetate [mi]

47. (3s,6s)-6-(dimethylamino)-4,4-diphenylheptan-2-yl Acetate

48. Levacetylmethadol [who-dd]

49. Zinc1530967

50. Levacetylmethadol [ema Epar]

51. Db01227

52. Benzeneethanol, Beta-(2-(dimethylamino)propyl)-alpha-ethyl-beta-phenyl-, Acetate(ester), (-)

53. Ncgc00247347-01

54. [s-(r*,r*)]-beta-[2-dimethylamino)propyl]-alpha-ethyl-beta-phenylbenzeneethanol Acetate (ester)

55. Ft-0700555

56. C08012

57. D04716

58. Q411799

59. (1s,4s)-(6-dimethylamino-4,4-diphenyl-heptan-3-yl) Acetate

60. 3-heptanol, 6-(dimethylamino)-4,4-diphenyl-, Acetate (ester), (3s,6s)-(-)- (8ci)

61. Benzeneethanol, .beta.-(2-(dimethylamino)propyl)-.alpha.-ethyl-.beta.-phenyl-, Acetate (ester), (-)-

62. Benzeneethanol, Beta-[(2s)-2-(dimethylamino)propyl]-alpha-ethyl-beta-phenyl-, Acetate (ester), (alphas)- (9ci)

2.4 Create Date
2004-09-16
3 Chemical and Physical Properties
Molecular Weight 353.5 g/mol
Molecular Formula C23H31NO2
XLogP34.3
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count3
Rotatable Bond Count9
Exact Mass353.235479232 g/mol
Monoisotopic Mass353.235479232 g/mol
Topological Polar Surface Area29.5 Ų
Heavy Atom Count26
Formal Charge0
Complexity404
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

For the treatment and management of opiate dependence. It is sometimes used to treat severe pain in terminal patients.


ORLAAM is indicated for the substitution maintenance treatment of opiate addiction in adults previously treated with methadone, as part of a comprehensive treatment plan including medical, social and psychological care.

ORLAAM should be administered under the supervision of physicians with experience in addiction treatment and whenever practicable, in centres specialising in the treatment of drug addiction.

ORLAAM is not intended for take home use.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Levomethadyl acetate (also known as LAAM) is a synthetic synthetic opioid analgesic with multiple actions quantitatively similar to those as morphine, the most prominent of which involve the central nervous system and organs composed of smooth muscle. However, levomethadyl acetate is more active and more toxic than morphine. The principal actions of therapeutic value are analgesia and sedation and detoxification or temporary maintenance in narcotic addiction. In this respect, the drug is similar to Methadone and also has structural similarities to it. The levomethadyl acetate abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe.


5.2 MeSH Pharmacological Classification

Analgesics, Opioid

Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)


5.3 ATC Code

N02AC


N - Nervous system

N07 - Other nervous system drugs

N07B - Drugs used in addictive disorders

N07BC - Drugs used in opioid dependence

N07BC03 - Levacetylmethadol


5.4 Absorption, Distribution and Excretion

Absorption

Levomethadyl acetate is rapidly absorbed from an oral solution.


5.5 Metabolism/Metabolites

Levomethadyl acetate is demethylated to nor-levomethadyl acetate which is again demethylated to dinor-levomethadyl acetate. This extensive first pass metabolism produces 2 metabolites that are more active than the parent drug.


5.6 Biological Half-Life

2.6 days


5.7 Mechanism of Action

Opiate receptors (Mu, Kappa, Delta) are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Levomethadyl acetate effectively opens calcium-dependent inwardly rectifying potassium channels (OP1 receptor agonist), resulting in hyperpolarization and reduced neuronal excitability.


ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty